BCLI

BRAINSTORM CELL THERAPEUTICS INC.. operates in the biological products, (no diagnostic substances) industry. listed on OTC. headquartered in NEW YORK, NY.

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) is publicly traded on OTC within the Healthcare sector , specifically in the Biological Products, (No Diagnostic Substances) industry. The company is headquartered in NEW YORK, NY.

Business classification: According to SEC filings, BRAINSTORM CELL THERAPEUTICS INC. falls under SIC code 2836 — Biological Products, (No Diagnostic Substances). This classification helps investors compare the company against peers in similar regulatory and operational environments.

Sector outlook: Companies in the Healthcare sector typically share exposure to similar macroeconomic factors — interest rates, regulatory shifts, and consumer demand patterns specific to this industry vertical. Investors evaluating BCLI should benchmark against other Healthcare stocks for comparative analysis.

Industry-specific factors: The Biological Products, (No Diagnostic Substances) industry has specific competitive dynamics — market share concentration, supply chain dependencies, and capital intensity that affect valuation. Compare BCLI with peer companies in Biological Products, (No Diagnostic Substances) to assess relative positioning.

Regulatory disclosures: With CIK 0001137883, BRAINSTORM CELL THERAPEUTICS INC. files mandatory disclosures with the U.S. Securities and Exchange Commission. These include 10-K annual reports, 10-Q quarterly reports, and 8-K material event filings — accessible via the official SEC EDGAR portal for fundamental research.

This page is for educational and research purposes only and does not constitute investment advice. Always conduct independent due diligence and consult a licensed financial advisor before making investment decisions.